Eli Lilly and Company (LLY)
Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions
Eli Lilly remains a 'strong buy' as I see robust revenue growth across obesity, diabetes, immunology, and oncology franchises. LLY's MOUNJARO and ZEPBOUND delivered Q1 2026 revenues of $8.66B [+125%] and $4.16B [+80%] respectively, driving a 56% YoY total revenue increase. Pipeline momentum is strong: FOUNDAYO launched, Retatrutide and Eloralintide advanced, and EBGLYSS/JAYPIRCA show double-digit growth with label expansion catalysts ahead.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims
Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO are two weight-loss and diabetes drug stocks that have been on completely different trajectories. Since the start of 2025, LLY is up nearly 30%, while NVO has plummeted more than 30%.
Signal: Eli Lilly Stock Remains a "Buy" After Earnings
Eli Lilly And Co (NYSE:LLY) has capitalized on last week's impressive first-quarter earnings report.
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.
Lilly commits additional $4.5 billion across Indiana manufacturing sites
Eli Lilly said on Wednesday it would commit an additional $4.5 billion investment across two of its three sites in Indiana, bringing the company's total capital expansion commitments in the state since 2020 to more than $21 billion.
Our Strongest Conviction Call: Eli Lilly Headed 21% Higher in 12 Months
Eli Lilly (NYSE:LLY | LLY Price Prediction) just delivered one of the strongest first quarters in big pharma history, but shares have pulled back sharply from their February peak.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly: Buying Opportunity Knocking On The Front Door Again (Rating Upgrade)
Eli Lilly (LLY) outperformed with robust Q1 results showing 56% revenue growth and an EPS of $8.55, calming the market's nerves and anxiety. LLY's market share gains in incretin analogs have plateaued near 60%, as competition with Novo Nordisk (NVO) intensifies. Foundayo's early launch challenges are nuanced, with global rollout and scaling capacity seen as promising levers for LLY through 2026.
LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised
LLY jumps after crushing Q1 estimates and raising 2026 outlook, powered by surging Mounjaro and Zepbound sales and strong global demand.
Demand for Weight-Loss Drugs Drove Blockbuster Results for Eli Lilly. Its Stock Is Surging.
Eli Lilly's stock is powering higher on fresh signs of booming demand for its weight-loss drugs. Will it be enough to drive a recovery for the stock?
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
The Food and Drug Administration proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's blockbuster obesity and diabetes medications from the list of drugs that outsourcing facilities can use for compounding. If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.
